Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. GNTA
GNTA logo

GNTA Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
0.861
Open
0.861
VWAP
0.86
Vol
5.68K
Mkt Cap
20.20M
Low
0.861
Amount
4.90K
EV/EBITDA(TTM)
--
Total Shares
23.43M
EV
8.28M
EV/OCF(TTM)
--
P/S(TTM)
--
Genenta Science SpA is an Italy-based company engaged in clinical-stage biotechnology research. The Company focuses on the development of lentivirus-based gene and cell therapies in cancer. It uses gene-based cytokine delivery to activate the immune system within the tumor providing the anti-tumor response. The Company not only operates locally but also is present in global markets, including the United States.
Show More

Events Timeline

(ET)
2026-01-27
05:30:00
Genenta Science Plans to Acquire Majority Stake in ATC
select
2025-11-24 (ET)
2025-11-24
05:09:37
Genenta Science Offers Update on TEM-GBM Research Study
select
2025-10-24 (ET)
2025-10-24
05:06:19
Genenta Science and Anemocyte Form Partnership to Enhance Plasmid DNA Technology
select
2025-07-01 (ET)
2025-07-01
05:22:04
Genenta Science announces follow-up observations in glioblastoma study
select
2025-05-07 (ET)
2025-05-07
07:28:25
Genenta Science, Anemocyte announce collaboration
select
2025-03-19 (ET)
2025-03-19
09:31:57
Genenta Science announces EUR 20M financing to expand pipeline
select
2025-01-09 (ET)
2025-01-09
05:46:06
Genenta Science announces amendment to pact with AGC Biologics
select
2024-10-02 (ET)
2024-10-02
06:35:48
Genenta Science secures approval for trial for metastatic Renal Cell Cancer
select

News

Yahoo Finance
4.5
02-28Yahoo Finance
Genenta Science Shifts Focus to Defense Sector
  • Strategic Shift: Genenta Science SPA announced a pivot from biotech to defense and national security, with an extraordinary shareholders meeting scheduled for March 26, marking a significant decision in response to changing market dynamics.
  • Acquisition Targets: The company aims to acquire profitable private Italian businesses generating around €5 million in annual EBITDA and has begun scouting for targets, having struck a deal to acquire ATC, a tactical rifles and special-forces weapon systems maker, contingent on meeting specific performance milestones.
  • Financial Projections: ATC projects €2.0 million in EBITDA for 2026, expecting to double this in 2027, which will provide robust financial support for Genenta's new business model and enhance its market position.
  • Ongoing Biotech Investment: Despite the shift to defense, Genenta plans to continue its biotech programs through partnerships, demonstrating the company's flexibility and foresight in diversifying its business strategy.
Newsfilter
8.5
02-27Newsfilter
Genenta Science Transforms into Saentra Forge, Appoints New Board Member
  • New Board Appointment: Genenta Science has appointed Paolo Salvato to the Board of Directors of ATC, marking the company's initial entry into defense technology manufacturing, which is expected to enhance its strategic position in the defense sector.
  • Acquisition Opportunity Evaluation: The company is evaluating majority-control acquisition opportunities in regulated national-security sectors, aiming to build a next-generation strategic industrial consolidator to support technology and scale-up initiatives.
  • Biotech Progress: The company announced that its manuscript on clinical findings from the Glioblastoma Multiforme trial has been accepted for publication by Nature Medicine, which is expected to provide significant validation of its scientific and clinical efforts, thereby enhancing market credibility.
  • Capital Market Potential: As a publicly listed company, Genenta Science plans to access capital through its Nasdaq listing to support its strategy of acquiring profitable industrial businesses, enhancing financial flexibility and driving long-term value creation.
Benzinga
4.5
01-27Benzinga
Genenta Science Transitions to Defense Sector Consolidator
  • Strategic Shift: Genenta Science announced its rebranding to Saentra Forge S.p.A. and plans to acquire privately held businesses with approximately €5 million in EBITDA, marking a strategic pivot towards the defense sector.
  • Funding Commitment: The company has entered into an agreement to provide €5.1 million in funding to ATC, which is projected to achieve around €4 million in revenue by 2026 and double its EBITDA by 2027, highlighting the growth potential of this new direction.
  • Clinical Milestones: Genenta has reached key clinical milestones aimed at establishing partnerships with major pharmaceutical and biotech firms to accelerate development, improve market access, and enhance strategic value.
  • Financial Outlook: Despite a 68.29% decline in stock over the past year, shares are currently trading 87.5% above the 20-day simple moving average, indicating short-term strength, with expectations of cash and equivalents reaching approximately $33 million by the end of 2025.
Benzinga
2.0
01-27Benzinga
Biomx Inc Shares Surge After 13D Filing Reveals Major Stake
  • Stake Increase: Pyu Pyu Capital disclosed a 19.99% stake in Biomx Inc through a 13D filing, causing the company's shares to surge 103.4% to $8.34 in pre-market trading, indicating strong market confidence in its future prospects.
  • Market Reaction: The dramatic rise in Biomx Inc's stock price reflects optimistic investor expectations regarding its potential growth opportunities, particularly in the context of strategic transformations within the biotechnology sector, which may attract further investor interest.
  • Industry Impact: The significant increase in Biomx Inc's stock price could positively influence other biotechnology companies, enhancing overall market confidence in the sector and potentially leading to increased capital inflows into related fields.
  • Investor Sentiment: This substantial stock price increase not only elevates Biomx Inc's market position but may also encourage other companies to adopt similar strategic initiatives to attract investors and enhance their competitive edge.
Yahoo Finance
4.5
01-27Yahoo Finance
Genenta Science Transforms into Defense Integrator with Strategic Acquisitions
  • Strategic Transformation: Genenta Science is shifting its focus to the defense and national security sectors, planning to acquire privately held businesses with established profitability, which is expected to enhance its market position under Italy's Golden Power regulations.
  • First Industrial Integration: The company has entered into an agreement with ATC to invest €5.1 million through a staged acquisition aimed at achieving a controlling stake, with ATC projecting revenues of €4 million in 2026 and €9 million in 2027, indicating strong growth potential.
  • Long-Term Strategic Shareholder: The Praexidia Foundation has become a long-term strategic shareholder, reinforcing the company's governance structure and ensuring consultation rights on significant transactions through a shareholders' agreement, enhancing stability in the defense sector.
  • Clinical Progress and Partnerships: Genenta has reached key clinical milestones in its cell therapy platform and plans to partner with pharmaceutical companies to leverage its technology in challenging tumor applications, which is expected to accelerate market access and enhance strategic value.
Globenewswire
5.0
2025-12-19Globenewswire
Genenta CEO Pierluigi Paracchi Acquires 30,000 ADS, Holding Reaches 10% of Outstanding Shares
  • Shareholding Increase: Genenta Science CEO Pierluigi Paracchi has acquired a total of 30,000 American Depositary Shares (ADS) through open-market purchases, bringing his total holdings to 2,326,129 shares, which represents approximately 10% of the company's outstanding share capital, reflecting confidence in the company's future prospects.
  • Market Signal: Paracchi's acquisition of shares without any reported sales indicates a strong belief in Genenta's long-term growth potential, which may bolster investor confidence in the company's stock price.
  • Clinical Progress: Genenta is conducting a Phase 1 trial for newly diagnosed Glioblastoma Multiforme patients, with preliminary results suggesting that its product candidate Temferon™ may have the potential to reprogram the tumor microenvironment, potentially enhancing treatment efficacy.
  • Future Outlook: The company has initiated a Phase 1/2a clinical study for metastatic Renal Cell Carcinoma, which, if successful, could further enhance its competitive position in the tumor immunotherapy market.
Wall Street analysts forecast GNTA stock price to rise
1 Analyst Rating
Wall Street analysts forecast GNTA stock price to rise
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.000
sliders
Low
7.00
Averages
7.00
High
7.00
Current: 0.000
sliders
Low
7.00
Averages
7.00
High
7.00
No data

No data

Valuation Metrics

The current forward P/E ratio for Genenta Science SPA (GNTA.O) is -2.46, compared to its 5-year average forward P/E of -8.73. For a more detailed relative valuation and DCF analysis to assess Genenta Science SPA's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-8.73
Current PE
-2.46
Overvalued PE
-3.05
Undervalued PE
-14.40

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-4.86
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.39
Undervalued EV/EBITDA
-10.11

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
25.80
Current PS
0.00
Overvalued PS
85.21
Undervalued PS
-33.61

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

best stock today for day trading
Intellectia · 3393 candidates
Price: $1.00 - $200.00Volume: >= 50,000List Exchange: XNYS, XNAS, XASE
Ticker
Name
Market Cap$
top bottom
RR logo
RR
Richtech Robotics Inc
1.12B
NVDA logo
NVDA
NVIDIA Corp
4.61T
INTC logo
INTC
Intel Corp
218.01B
NUWE logo
NUWE
Nuwellis Inc
6.31M
AAL logo
AAL
American Airlines Group Inc
9.10B
F logo
F
Ford Motor Co
55.04B
take me to stock radar
Intellectia · 53 candidates
Region: USPrice: $1.00 - $30.00Volume: >= 1,000,000Price Change Pct: $-25.00 - $25.00Relative Vol: >= 2List Exchange: XNYS, XNAS
Ticker
Name
Market Cap$
top bottom
SATL logo
SATL
Satellogic Inc
729.00M
HUYA logo
HUYA
HUYA Inc
1.01B
GNTA logo
GNTA
Genenta Science SPA
30.70M
ATOM logo
ATOM
Atomera Inc
105.50M
BAER logo
BAER
Bridger Aerospace Group Holdings Inc
173.85M
UROY logo
UROY
Uranium Royalty Corp
683.86M

Whales Holding GNTA

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Genenta Science SPA (GNTA) stock price today?

The current price of GNTA is 0.8619 USD — it has increased 0

What is Genenta Science SPA (GNTA)'s business?

Genenta Science SpA is an Italy-based company engaged in clinical-stage biotechnology research. The Company focuses on the development of lentivirus-based gene and cell therapies in cancer. It uses gene-based cytokine delivery to activate the immune system within the tumor providing the anti-tumor response. The Company not only operates locally but also is present in global markets, including the United States.

What is the price predicton of GNTA Stock?

Wall Street analysts forecast GNTA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GNTA is7.00 USD with a low forecast of 7.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Genenta Science SPA (GNTA)'s revenue for the last quarter?

Genenta Science SPA revenue for the last quarter amounts to NaN USD, decreased

What is Genenta Science SPA (GNTA)'s earnings per share (EPS) for the last quarter?

Genenta Science SPA. EPS for the last quarter amounts to USD, decreased

How many employees does Genenta Science SPA (GNTA). have?

Genenta Science SPA (GNTA) has 13 emplpoyees as of March 11 2026.

What is Genenta Science SPA (GNTA) market cap?

Today GNTA has the market capitalization of 20.20M USD.